局部晚期胰腺癌的治疗进展

摘要/Abstract

摘要：局部晚期胰腺癌目前治疗的主要手段是放化疗联合姑息性手术的综合治疗，目的在于延长患者生命的同时提高其生活质量。吉西他滨是目前的标准治疗，以其为基础的联合方案的疗效已得到肯定，与靶向药物联合亦有一定的疗效。新的化疗药物和靶向药物的涌现，为局部晚期胰腺癌的治疗提供了更多的途径。

关键词:胰腺肿瘤,药物疗法,放射疗法

Abstract:Treatment for locally advanced pancreatic cancerWANG Meng, YANG Jiyuan. Corresponding author:【Abstract】Combined therapy consisting of radiotherapy, chemotherapy and palliative surgery is the primary management for locally advanced pancreatic cancer, with the purpose of prolonging survival and improving life quality. Gemcitabine is the standard chemotherapy at present. Gemcitabinebased combinations show a definite effect, and the combination with targeted drugs also has a certain degree of efficacy. The development of new chemotherapy drugs and targeted drugs provides more ways for the teatment of locally advanced pancreatic cancer.

Key words:Pancreatic neoplasms,Drug therapy,Radiotherapy

王梦, 杨继元. 局部晚期胰腺癌的治疗进展[J]. 国际肿瘤学杂志, 2013, 40(11): 850-853.

WANG Meng, YANG Ji-Yuan. [J]. Journal of International Oncology, 2013, 40(11): 850-853.

参考文献

［1］ Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet, 2011, 378(9791): 607-620．［2］ Ueno H, Okusaka T, Ikeda M, et al．A phase Ⅰ study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology, 2005, 69(5):421-427．［3］ Ueno H, Okusaka T, Furuse J, et al. Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastaticpancreatic cancer. Jpn J Clin Oncol, 2011, 41(8):953-958．［4］ Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary endpoints analyses. Br J Cancer, 2008,99(1):6-13. ［5］ Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19):1817-1825．［6］ Peddi PF, Lubner S, McWilliams R, et al. Multiinstitutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP, 2012, 13(5):497-501．［7］ Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase Ⅲ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys, 2005, 62(5):1345-1350．［8］ Chauffert B, Mornex F, Bonnetain F, et al. Phase Ⅲ trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Ann Oncol, 2008, 19(9):1592-1599．［9］ Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus Gemcitabine plus Radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 2011, 29(31):4105-4112．［10］ Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine based or capecitabine based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP):a multicentre, randomised, phase 2 trial. Lancet Oncol, 2013, 14(4):317-326．［11］ Shinchi H, Maemura K, Mataki Y, et al. A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci, 2012, 19(2):152-158．［12］ Kim HM， Bang S， Park JY， et al． Phase Ⅱ trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.Cancer Chemother Pharmacol， 2009，63(3):535-541. ［13］ Shinchi H， Maemura K， Mataki Y， et al． A phase Ⅱ study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S1 alone for locally　advanced pancreatic cancer．J Hepatobiliary Pancreat Sci， 2012，19(2):152-158．［14］ Crane CH， Winter K， Regine WF， et al． Phase Ⅱ study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabineand bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411．J Clin Oncol， 2009，27(25):4096-4102．［15］ Xiong HQ， Rosenberg A， LoBuglio A， et al． Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial. J Clin Oncol， 2004，22(13):2610-2616．［16］ Philip PA, Benedetti J, Corless CL, et al． Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205. J Clin Oncol， 2010，28(22):3605-3610．［17］ Strumberg D， Schultheis B， Scheulen ME， et al． Phase Ⅱ study of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer． Invest New Drugs， 2012，30(3):1138-1143. ［18］ Strumberg D， Schultheis B， Scheulen ME， et al． Safety,efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody,in patients with locally advanced or metastatic pancreatic cancer． Int J Clin Pharmacol Ther， 2010，48(7):473-475．［19］ Crane CH, Mason K, Janjan NA, et al． Initial experience combining cyclooxygenase2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol， 2003，26(4)：S81-S84．［20］ Xiong HQ， Rosenberg A， LoBuglio A， et al. Cetuximab,a monoclonal antibody targeting the epidermal growth factor receptor, in combination withgemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial．J Clin Oncol， 2004，22(13):2610-2616．［21］ Ferrari V， Valcamonico F， Amoroso V， et al． Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase Ⅱ trial. Cancer Chemother Pharmacol， 2006，57(2):185-190.

[1]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[8]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[9]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	许萌, 姜伟, 朱海涛, 曹雄锋.癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[12]	石小琪, 汪红艳.肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[13]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅.Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[14]	耿睿, 马俊强, 郭强, 牛钊峰.老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[15]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇.重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价